176 related articles for article (PubMed ID: 36313683)
1. The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis.
Guo X; Zhang Y; Jiao H; Miao X
Front Oncol; 2022; 12():925560. PubMed ID: 36313683
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis.
Xue S; Song G; Yu J
Sci Rep; 2017 Jun; 7(1):4231. PubMed ID: 28652622
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset.
Wang H; Xiao Y; Ren X; Wan D
Bioengineered; 2021 Dec; 12(2):10366-10378. PubMed ID: 34903133
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis.
Hao C; Chen G; Zhao H; Li Y; Chen J; Zhang H; Li S; Zhao Y; Chen F; Li W; Jiang WG
Front Oncol; 2020; 10():1015. PubMed ID: 32670884
[No Abstract] [Full Text] [Related]
6. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
Wang Q; Liu F; Liu L
Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
Li J; Wang P; Xu Y
PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study.
Jin L; Gu W; Li X; Xie L; Wang L; Chen Z
Ther Adv Med Oncol; 2020; 12():1758835920962362. PubMed ID: 33062064
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.
Piao J; Lim HJ; Lee M
Obstet Gynecol Sci; 2020 May; 63(3):346-356. PubMed ID: 32489980
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
[TBL] [Abstract][Full Text] [Related]
14. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
15. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.
Huang ZL; Liu S; Wang GN; Zheng SH; Ding SR; Tao YL; Chen C; Liu SR; Yang X; Chang H; Wang XH; Xia YF
Cancer Cell Int; 2019; 19():141. PubMed ID: 31139018
[TBL] [Abstract][Full Text] [Related]
17. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y
Front Oncol; 2019; 9():897. PubMed ID: 31620360
[No Abstract] [Full Text] [Related]
18. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
19. Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
Gu X; Dong M; Liu Z; Mi Y; Yang J; Zhang Z; Liu K; Jiang L; Zhang Y; Dong S; Shi Y
Cancer Cell Int; 2019; 19():146. PubMed ID: 31143091
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of programmed cell death ligand-1 expression in the tumor-infiltrating immune cells of patients with lung cancer: A meta-analysis.
Berele BA; Yang G; Wu T
Mol Clin Oncol; 2021 Aug; 15(2):167. PubMed ID: 34194745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]